Public Companies
Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics
The company also opened a new clinic in Norway.
The post Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics appeared first on Green Market R…
Canada-based biotech firm Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) has lost its head of psychedelic medicine, but due to the loss, it gained full ownership in one of its clinics.
Dr. Ben Sessa resigned his position as head of psychedelic medicine at the company, effective April 13, Awakn disclosed in a press release. As part of the exit, Sessa is transferring his 49% ownership in Awakn Bristol Limited, with Awakn Clinics Bristol in England, to Awakn Life Sciences Inc., giving the company 100% ownership in the British psychedelics clinic.
In the same press release, Awakn announced that it had commenced treatments for alcohol use disorder with patients at a Manhattan facility run by Nushama Inc., one of Awakn’s licensing partners for its product line of Awakn Kare.
And on March 1, Awakn opened Awakn Clinics Trondheim in Norway for ketamine-assisted therapy. The opening marks the company’s fourth clinic globally and its second in Norway.
Awakn made headlines in February when the company was accused by OTC Markets group of running a stock promotion scheme, an allegation it denied.
The post Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics appeared first on Green Market Report.
ketamine psychedelic therapy treatment clinics psychedelics otc awakn life sciences awakn
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin6 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation5 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics5 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics6 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research